drugset / Trial / NCT06246552

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

NCT06246552

Phase 2 Completed 480 enrolled Jetema USA Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines

Timeline

Start
2024-10-26
Primary completion
2025-06-05
Completion
2025-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject JTM201 Unknown 20 iu Intramuscular

Indications

No indication recorded.